Heron Therapeutics, Inc. has announced the signing of a significant Framework Agreement with Patheon Austria GmbH & Co KG, with Thermo Fisher Scientific Inc. involved for specific purposes. Under the terms of this agreement, Heron Therapeutics commits to purchasing 38,400 kg of products from Patheon by the end of 2026. This deal also includes Patheon providing manufacturing, supply, ongoing stability studies, and warehousing services for these products. The new agreement supersedes some previous arrangements between the two companies, integrating them into a comprehensive Manufacturing and Supply Agreement. The details of this contract will be filed with Heron's upcoming quarterly report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.